In Vivo Toxicology Market by Type (Instrument and Consumables), Test Type (Acute, Sub-acute, Sub-chronic, and Chronic test type), Testing Facility (Outsourced Testing Facility And In-House Testing Facility), Toxicity End Points (Immunotoxicity, Systemic toxicity, Carcinogenicity, Genotoxicity, Developmental & reproductive toxicity (DART), and Other toxicity endpoints), End User (Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Other End Users): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026823 | Pages: 100 | Industry: Pharmaceuticals | Date: Oct 2022 | Type: Global

The market crossed US$ 5.77 billion mark in 2022 and is expected to hit US$ 8.94 billion by 2030, recording a CAGR of 5.64% during the forecast period.

Increase in carcinogenicity testing has fueled the growth of in vivo toxicology testing market

Toxicology testing is increasing and there are various methods such as in vitro, and in silico toxicology tests used. Most toxicology tests can be performed by other means but there is a certain test that can only be performed with the help of in vivo toxicology testing. This includes carcinogenicity development, and it is one of the most performed tests nowadays. Additionally, the increase in drug development has further contributed to the growth of in vivo toxicology testing market. The consumables segment is dominating the growth of the market owing to the increased use of reagents, assays, and other biological samples which are likely to proliferate the growth of in vivo toxicology market growth.

Within the report, the market is segmented into type, test type, testing facility, toxicity end points end user, and geography. By type, the market is bifurcated into instruments and consumables. Based on test type, the market is segmented into acute, sub-acute, sub-chronic, and chronic test types. By testing facility, the marker is categorized into outsourced testing facility and in-house testing facility. Based on toxicity end points, the market is categorized into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental & reproductive toxicity, and other toxicity endpoints. Based on end user, the market is divided into academic and research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users. Geographically, the market is subsegmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Increased use of humanized models is expected to empower the growth of in vivo toxicology market

In vivo toxicology is a test that helps in understanding the biological response towards toxic elements and assists in minimizing the adverse effects of various molecules within the body. In vivo toxicology testing has various applications in different fields such as food & beverage, Healthcare, environment, and others to study the impact of the toxic substance. The research and testing for humans required models which are like humans, and it has increased the demand for humanized animal models for various research such as cancer, hepatitis, infectious diseases, and AIDS/HIV. Thus, an increase in humanized models for the research and study of toxic substances is expected to create futuristic opportunities in the market.

Increased adoption of in vivo toxicology is one of the major factors accelerating market growth.

The end users for in vivo toxicology market include academic and research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users. Within these end users, academic and research institutes are one such end user, wherein the use of in vivo toxicology is used significantly used and most of the research papers are published in collaboration with these institutes.  However, pharmaceutical & biotechnology companies and contract research organizations are expected to gain traction over the forecast period and support the growth of in vivo toxicology market.

Recent strategic developments in In Vivo Toxicology market

The in vivo toxicology market has undergone several significant developments, and a few of these have been mentioned below:

  • In January 2022, Inotiv, Inc. has completed the purchase of Integrated Laboratory Systems, LLC (“ILS”), a portfolio company of Sier Capital Partners. ILS is a contract research organization, located in Morrisville, North Carolina, specializing in genetic toxicology, in vivo and in vitro toxicology, pathology, molecular biology, bioinformatics and computational toxicology services.
  • In April 2021, Waters Corporation and Genovis AB have collaborated to develop and market complete routine biopharmaceutical characterization workflows based on the Waters BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. The goal of the collaboration is to develop automated workflows for the rapid and consistent characterization of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs in bioprocess development, formulation, stability testing and quality control (QC).

The in vivo toxicology market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Charles River Laboratories, The Jackson Laboratory, Envigo, JANVIER LABS, Thermo Fisher Scientific, and Agilent Technologies are among the prominent players operating in the market.

Target audience for the report:

  • Raw material providers
  • Biotechnology-related service providers
  • Biotechnology & research-related associations, organizations, forums, and alliances
  • Government bodies, such as regulating authorities and policy makers
  • Venture capitalists, private equity firms, and start-up companies
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Product:
    • Instruments
    • Consumables
      • Reagents & Kits
      • Animal Models
        • Mice Models
        • Rat Models
        • Other Animal Models
  • Test Type:
    • Acute
    • Sub-acute
    • Sub-chronic
    • Chronic test type
  • Testing Facility:
    • outsourced testing facility
    • In-house testing facility
  • Toxicity End Points:
    • Immunotoxicity
    • Systemic toxicity
    • Carcinogenicity
    • Genotoxicity
    • Developmental & reproductive toxicity (DART)
    • Other toxicity endpoints
  • End User:
    • Academic and Research Institutes
    •  Pharmaceutical & Biotechnology Companies
    •  Contract Research Organizations
    •  Other End Users
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
    • Charles River Laboratories
    • The Jackson Laboratory
    • Envigo
    • Thermo Fisher Scientific
    • Agilent Technologies
    • Harbour BioMed
    • Crown Biosciences
    • PerkinElmer
    • Bio-Rad Laboratories


The List of Companies
- Charles River Laboratories
- The Jackson Laboratory
- Envigo
- Thermo Fisher Scientific
- Agilent Technologies
- Harbour BioMed
- Crown Biosciences
- PerkinElmer
- Bio-Rad Laboratories

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Purchase Options
Single User License
Site License
Enterprise License